China
Africa
Explore chapters and articles related to this topic
The Role of the Gut Microbiome in Cardiovascular Disease
Published in Stephen T. Sinatra, Mark C. Houston, Nutritional and Integrative Strategies in Cardiovascular Medicine, 2022
To Reduce High Levels of Beta-Glucuronidase: Decrease meat intake and increase insoluble fiber.Take probiotics.Consider Silybum marianum for liver support.Take calcium-D-glucarate.
Managing Pain in the Presence of Autoimmune Disease
Published in Sahar Swidan, Matthew Bennett, Advanced Therapeutics in Pain Medicine, 2020
Beta glucuronidase: This tends to self-correct as the good bacteria should make an enzyme to break it down. If they don’t start doing this work by the first retest, consider calcium D-glucarate supplementation. Or possibly add a combination insoluble/soluble fiber supplement to bind up the toxins until they can be cleared from the gut and help to feed the good bacteria as a “prebiotic,” food for the good bacteria.
Unproven and Controversial Forms of Immunotherapy
Published in Richard F. Lockey, Dennis K. Ledford, Allergens and Allergen Immunotherapy, 2014
Haig Tcheurekdjian, Abba I. Terr
None of the published research findings in patients treated by enzyme-potentiated desensitization substantiates this theory. The effectiveness of this method and the presumed pharmacologic property of beta-glucuronidase on the immune system are based on anecdotal evidence or clinical trials of generally inferior quality. Several published double-blind reports claim symptomatic improvements in adults or children with allergic rhinoconjunctivitis or asthma along with conflicting results of immunological changes [28–36]. These studies suffer from a number of limitations including small sample sizes, brief follow-up periods, and/or lack of objective measures of disease activity. A double-blind, placebo- controlled trial of enzyme-potentiated desensitization for large local reactions to mosquito bites, conducted by investigators who had identified this therapy as being effective in a retrospective analysis, showed no difference between active treatment and placebo [36]. The most rigorously performed double-blind study, which included 183 subjects and objective outcome measures, showed no benefit of enzyme-potentiated desensitization in comparison to placebo for children with allergic rhinitis [35]. Furthermore, the United States Food and Drug Administration has banned the import of enzyme-potentiated desensitization products prepared by the primary manufacturer, because these allergens are unlicensed in the United States and have been brought previously into the country illegally [37].
A Psychonaut’s Experience of Intoxication with Multiple Classes of Drugs Including Novel Psychoactive Substance 2-fluorodeschloroketamine: Case Report and Urinary Analysis
Published in Journal of Psychoactive Drugs, 2022
Kristina Domanski, Steven W Fleming, Hayden Maag, Emily Bouso Raley, Joshua DeBord, Brooks Wright, Roya Mahana
A urine sample was obtained from the patient by the Toxicology team and sent for further analysis. An immunoassay screen and an untargeted LC/QToF drug screen were performed. To detect novel psychoactive substances with the ability to perform structural elucidation of metabolites, high-resolution mass spectrometry is commonly utilized (Fleming et al. 2017; Vikingsson et al. 2019; Wallgren et al. 2020). The untargeted analysis performed on the urine sample utilized the Waters Forensic Toxicology methodology that was previously discussed by Mardal et al. (2019). Briefly, the urine sample (0.23 mL) was treated with 0.020 mL of deuterated internal standard mixture, 0.020 mL of beta-glucuronidase, and 0.050 mL of 0.1 M ammonium acetate buffer. The samples were hydrolyzed for 15 minutes at 60 C and allowed to cool to room temperature. The samples were extracted using SLE cartridges (Phenomenex, Torrance, CA). The eluents were evaporated to dryness, reconstituted with 0.20 mL of aqueous mobile phase (0.1% formic acid). The extracts were subsequently analyzed by an Acquity UPLC I Class coupled to an Acquity G2-X2 Q/ToF mass spectrometer (Waters Corp., Milford, MA) using positive electrospray ionization. Injections (0.010 mL) were separated within 15 minutes using a gradient profile of aqueous mobile phase and organic mobile phase (0.01% formic acid in acetonitrile) with a 0.4 mL/min flow rate on a Waters HSS C18 (2.1 mm × 150 mm, 1.8 µm) column that was maintained at 50°C. Data acquisition was performed using UNIFI v1.9.
A New Approach to Polycystic Ovary Syndrome: The Gut Microbiota
Published in Journal of the American College of Nutrition, 2020
Gamze Yurtdaş, Yasemin Akdevelioğlu
In addition to the above-mentioned mechanisms, in recent studies, it has been suggested that androgens may lead to the development of PCOS by shaping the gut microbiota composition (10, 40, 41). Recent studies have shown that changes in gut microbiota are associated with hyperandrogenism in women with PCOS (40, 41). However, there is a limited number of studies to explain how sex steroids affect gut microbiota. It is thought that sex steroids may directly influence the composition of gut microbiota by changing beta-glucuronidase activity and energy production (10, 77). It has also been reported that sex steroids may indirectly regulate gut microbiota by the activation of steroid receptors in the host (10). Another potential effect is that changes in sex steroids are likely to alter the immune response by regulating the integrity of the intestinal barrier. Reduction of the integrity of the intestinal barrier results in the infiltration of gram-negative bacteria into the circulation and activation of the peripheral inflammatory response generated by LPS (10). It should be noted that gut microbiota may also play a role in PCOS by regulating sex steroids (40). However, the role of gut microbiota on steroid regulation is not fully understood (78). Future studies need to investigate mechanisms behind the relationship between hyperandrogenism and the gut microbiome.
Prodrugs for targeted cancer therapy
Published in Expert Review of Anticancer Therapy, 2019
Carla Souza, Diogo Silva Pellosi, Antonio Claudio Tedesco
One of the initial problems of ADEPT was the persistence of enzyme activity in the blood, which could result in a widespread activation of the prodrug. An anti-PEG antibody has also been utilized to clear an antibody-beta-glucuronidase conjugate that had been PEGylated. This method may result in efficient clearance [136]; however, an immune response to PEG must be taken into consideration for human applications [137]. Furthermore, the low number of tumor-selective antigens also limit the applicability of the ADEPT strategy, leading to the transformation of prodrugs in non-cancerous tissues [14,99]. Other drawbacks include the limited delivery of conjugates in poorly vascular tumors, the cost, and the difficulty involved in the development and cleaning of antibodies [3,14].